Since CXCR signaling upregulates multiple genes related to metastasis and since clinical MMP inhibition is not currently feasible, whereas CXCR4 blockade is possible with drugs such as AMD3100, CXCR4 may be a fruitful therapeutic target to inhibit some of the metastatic potential of chondrosarcoma cells. This evidence concerns the gene CXCR4 and chondrosarcoma.